Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management ...

General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced a series of new ...

PLEASANTON, Calif., Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will ...

Genomics, Inc. (NASDAQ:TXG – Get Free Report) has received a consensus recommendation of “Hold” from the seventeen analysts ...

Genomics (NASDAQ:TXG – Get Free Report) is projected to announce its earnings results after the market closes on Thursday, February 20th. Analysts expect 10x Genomics to post earnings of ($0.29) per ...

Analysts at Leerink Partnrs decreased their Q1 2025 earnings estimates for shares of 10x Genomics in a research note issued to investors on Thursday, February 13th. Leerink Partnrs analyst P. Souda ...

Three of IWS's underlying holdings with notable upside to their analyst target prices are Ionis Pharmaceuticals Inc (Symbol: IONS), 10x Genomics Inc (Symbol: TXG), and Enovis Corp (Symbol ...

10x Genomics (NASDAQ:TXG), a leading player in the single-cell and spatial genomics technologies sector, finds itself at a critical juncture as it navigates through a challenging market environment.

Stock analysts at William Blair issued their Q3 2025 earnings per share estimates for 10x Genomics in a report issued on Thursday, February 13th. William Blair analyst M. Larew expects that the ...